MediciNova, Inc. To Present At The 2006 Pacific Growth Equities Life Sciences Growth Conference

SAN DIEGO, June 5 /PRNewswire/ -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced that Kenneth W. Locke, Ph.D., Chief Business Officer of MediciNova, will present a Company overview at 8:30 AM, Pacific Standard Time on Monday, June 12, at the 2006 Pacific Growth Equities Life Sciences Growth Conference. The Conference is being held at the InterContinental Mark Hopkins Hotel in San Francisco.

An archive of the presentation will be available for replay following the conference and will be available on MediciNova's corporate Web site at www.medicinova.com.

About MediciNova

MediciNova, Inc. is a publicly traded specialty pharmaceutical company focused on accelerating the global development and commercialization of innovative pharmaceutical products. MediciNova's pipeline, which includes several compounds in clinical testing, targets a variety of prevalent medical conditions, including cancer, asthma, Generalized Anxiety Disorder, multiple sclerosis, interstitial cystitis, preterm labor and urinary incontinence. For more information on MediciNova, Inc., please visit www.medicinova.com.

This press release may contain "forward looking statements" as defined by the Securities and Exchange Commission. All statements, other than statements of historical facts, included in this press release that address activities, events or developments that the Company expects, believes or anticipates will or may occur in the future are forward-looking statements. These statements are based on certain assumptions made by the Company based on management's experience and perception of historical trends, current conditions, expected future developments and other factors it believes are appropriate in the circumstances. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual results to differ materially from those implied or expressed by the forward-looking statements. These risks include the risk factors detailed in MediciNova's Securities and Exchange Commission.

CONTACT: Shintaro Asako, Vice-President Accounting and Administration ofMediciNova, Inc., +1-858-373-1500, asako@medicinova.com

Web site: http://www.medicinova.com/